Medsea Estates Group PLC
20 December 2004
For immediate release
20 December 2004
MEDSEA IN MULTI-MILLION POUNDS PROPERTY DEAL
Promilorci, S.L, a company in which Medsea Estates Group PLC holds a 13 per cent
interest, has bought development rights to a 4.5 million sq ft plot of land in
Murcia, Spain at a cost of €20 million (approximately £13.4 million). Promilorci
intends to develop up to 786 residential properties on the site.
Medsea will supervise everything related to the sales and marketing of the
properties on behalf Promilorci and Medsea's subsidiary, Euromed, acting as
principle agent, will commence marketing the development in the UK and Ireland
in the New Year through its links with some 150 independent property agents.
As stated in the Admission to AIM document, Euromed was established to broaden
the scope of the Group's activities so that it could obtain exclusive
arrangements with some developers for the sale of properties in prime
residential locations.
This is Euromed's first exclusive arrangement, enabling it to act in a promoter
type role rather than Medsea's traditional approach of entering into commission
arrangements with developers and promoters to pre-sell properties under
construction.
The project, known as the Nuevo Torre Guil development, is within a large
forested area that is just six miles from the city of Murcia, one of the most
important Spanish destinations for national and international tourism. The
Murcia region has experienced significant growth and ranks fifth for foreign
investment in Spain with Madrid and Barcelona taking the first two places as
capital investment centres.
The new homes will comprise two-storey, two to three bedroom semi-detached
houses which with prices starting from €180,000. The showhouse will be completed
in May 2005 and the first properties will be under construction by September of
that year.
Says Medsea Chairman Tony Gatehouse: 'This is an exciting move for Medsea.
Murcia is one of the key tourist destinations in Spain and last year it was
visited by over three quarters of a million people. Almost a third of the best
beaches along the Spanish Mediterranean coast are located here, the climate is
excellent and the region's infrastructure is impressive with major networks of
roads, good rail transport and easy access to airports. This all makes it a very
attractive place in which to buy property.'
Medsea had originally intended to hold a 20 per cent stake in Promilorci but the
project has attracted further investment interest from important business
associates in the Murcia region and the share capital has been increased thus
reducing Medsea's holding to 13 per cent. The Group's partners in Promilorci are
Axis Cost Blanca S.L., with 16 per cent, Sevensuns Inversions S.L. (16 per
cent), Mr Jose Montoya del Moral (5 per cent) and Mr Ricardo-Jose Montoya Del
Morata (5 per cent). Other shareholders own the balance of 45 per cent.
For further information contact:
Tony Gatehouse, Chairman
Medsea Estates Group PLC 0034 96 570 40 02
Juan Carlos Rodriguez Martinez, Chief Executive
Medsea Estates Group PLC 0034 96 570 40 02
Roland Cornish
Beaumont Cornish Limited 020 7628 3396
Terry Garrett/ Alex White
Weber Shandwick Square Mile 0207 067 0700
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.